An update on intravitreal implants in use for eye disorders

Drugs of Today

Volumn 50, Issue 3, 2014, Pages 239-249

  Lambiase, A ^a   Abdolrahimzadeh, S ^b   Recupero, S M ^c  

^a Organi di Senso Department   (Italy)

^b POLICLINICO UMBERTO I   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Dexamethasone; Eye disorders; Fluocinolone acetonide; Intravitreal

Indexed keywords

DEXAMETHASONE; FLUOCINOLONE ACETONIDE; GANCICLOVIR; POLYETHYLENE TEREPHTHALATE; STEROID;

CATARACT; CORNEA EDEMA; DIABETIC MACULAR EDEMA; DRUG DELIVERY SYSTEM; ENDOPHTHALMITIS; EYE DISEASE; HUMAN; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE ABNORMALITY; INTRAVITREAL IMPLANT; MEDICAL DEVICE COMPLICATION; PHASE 2 CLINICAL TRIAL (TOPIC); PSEUDOPHAKIA; PSEUDOPHAKIC CYSTOID MACULAR EDEMA; RETINA DETACHMENT; RETINA MACULA CYSTOID EDEMA; RETINA MACULA EDEMA; RETINA VEIN OCCLUSION; REVIEW; TOOL USE; TREATMENT DURATION; UVEITIS; VITREOUS HEMORRHAGE;

DEXAMETHASONE; EYE DISORDERS; FLUOCINOLONE ACETONIDE; INTRAVITREAL;

ANIMALS; DELAYED-ACTION PREPARATIONS; DRUG DELIVERY SYSTEMS; DRUG DESIGN; DRUG IMPLANTS; DRUG MONITORING; EYE DISEASES; GLUCOCORTICOIDS; HUMANS; PATIENT SELECTION; POLYMERS; TIME FACTORS;

EID: 84897470895     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2014.050.03.2103755     Document Type: Review

References (66)

1. Edelhauser, H.F., Rowe-Rendleman, C.I., Robinson, M.R. et al. Ophthalmic drug delivery systems for the treatment of retinal diseases: basic research to clinical applications. Invest Ophthalmol Vis Sci 2010, 51(11): 5403-20.
2. Maurice, D. Review: Practical issues in intravitreal drug delivery. J Ocul Pharmacol Ther 2001, 17(4): 393-401. (Pubitemid 32888812)
3. Choonara, Y.E., Pillay, V., Danckwerts, M.P. et al. A review of implantable intravitreal drug delivery technologies for the treatment of posterior segment eye diseases. J Pharm Sci 2010, 99(5): 2219-39.
4. Musch D.C., Martin, D.F., Gordon, J.F. et al. The Ganciclovir Implant Study group. Treatment of cytomegalovirus retinitis with a sustained-release ganciclovir implant. N Engl J Med 1997, 337(2): 83-90. (Pubitemid 27284393)
5. Jaffe, G.J., McCallum, R.M., Branchaud, B., Skalak, C., Butuner, Z., Ashton, P. Long-term follow-up results of a pilot trial of a fluocinolone acetonide implant to treat posterior uveitis. Ophthalmology 2005, 112(7): 1192-8.
6. Jaffe, G.J., Martin, D., Callanan, D., Pearson, P.A., Levy, B., Comstock, T., Fluocinolone Acetonide Uveitis Study Group. Fluocinolone acetonide implant (Retisert) for noninfectious posterior uveitis: thirty-four-week results of a multicenter randomized clinical study. Ophthalmology 2006, 113(6): 1020-7. (Pubitemid 43795240)
7. Pavesio, C., Zierhut, M., Bairi, K., Comstock, T.L., Usner, D.W., Fluocinolone Acetonide Study Group. Evaluation of an intravitreal fluocinolone acetonide implant versus standard systemic therapy in noninfectious posterior uveitis. Ophthalmology 2010, 117(3): 567-75.e1.
8. Callanan, D.G., Jaffe, G.J., Martin, D.F., Pearson, P.A., Comstock, T.L. Treatment of posterior uveitis with a fluocinolone acetonide implant: three-year clinical trial results. Arch Ophthalmol 2008, 126(9): 1191-201.
9. Jain, N., Stinnett, S.S., Jaffe, G.J. Prospective study of a fluocinolone acetonide implant for chronic macular edema from central retinal vein occlusion: thirty-six-month results. Ophthalmology 2012, 119(1): 132-7.
10. Pleyer, U., Kellmann, M., Winterhalter, S., Thurau, S. Ozurdex: a new therapeutic option in uveitis-clinical outcome from two German uveitis centers. Annu Meet Assoc Res Vision Ophthalmol (ARVO) (May 6-9, Fort Lauderdale) 2012, Abst 2249.
11. Kane, F.E., Burdan, J., Cutino, A., Green, K.E. Iluvien: a new sustained delivery technology for posterior eye disease. Expert Opin Drug Deliv 2008, 5(9): 1039-46.
12. Lee, S.S., Hughes, P., Ross, A.D., Robinson, M.R. Biodegrad - able implants for sustained drug release in the eye. Pharm Res 2010, 27(10): 2043-53.
13. Querques, G., Lattanzio, R., Querques, L. et al. Impact of intravitreal dexamethasone implant (ozurdex) on macular morphology and function. Retina 2014, 34(2): 330-41.
14. Evaluation of grid pattern photocoagulation for macular edema in central vein occlusion. The Central Vein Occlusion Study Group M report. Ophthalmology 1995, 102(10):1425-33.
15. Argon laser photocoagulation for macular edema in branch vein occlusion. The Branch Vein Occlusion Study Group. Am J Ophthalmol 1984, 98(3): 271-82.
16. Ip, M.S., Scott, I.U., VanVeldhuisen, P.C. et al. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with observation to treat vision loss associated with macular edema secondary to central retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 5. Arch Ophthalmol 2009, 127(9):1101-14.
17. Haller, J.A., Bandello, F., Belfort, R., Jr. et al. Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology 2010, 117(6): 1134-46.e3.
18. Haller, J.A., Bandello, F., Belfort, R., Jr. et al. Dexa - methasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion twelve-month study results. Ophthalmology 2011, 118(12):2453-60.
19. Capone, A., Singer, M.A., Dodwell, D.G. et al. Efficacy and safety of two or more dexamethsone intravitreal implant injections for treatment of macular edema related to retinal vein occlusion (SHASTA study). Retina 2014, 34(2): 342-51.
20. Brown, D.M., Campochiaro, P.A., Singh, R.P. et al. Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology 2010, 117(6): 1124-33.e1.
21. Campochiaro, P.A., Brown, D.M., Awh, C.C. et al. Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve-month outcomes of a phase III study. Ophthalmology 2011, 118(10): 2041-9.
22. Heier, J.S., Campochiaro, P.A., Yau, L. et al. Ranibizumab for macular edema due to retinal vein occlusions: long-term follow- up in the HORIZON trial. Ophthalmology 2012, 119(4): 802-9.
23. Campochiaro, P.A., Heier, J.S., Feiner, L. et al. Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology 2010, 117(6): 1102-12.e1.
24. Luttrull, J.K., Dorin, G. Subthreshold diode micropulse laser photocoagulation (SDM) as invisible retinal phototherapy for diabetic macular edema: a review. Curr Diabetes Rev 2012, 8(4): 274-84.
25. Diabetic Retinopathy Clinical Research Network, Beck, R.W., Edwards, A.R. et al. Three-year follow-up of a randomized trial comparing focal/grid photocoagulation and intravitreal triamcinolone for diabetic macular edema. Arch phthalmol 2009, 127(3): 245-51.
26. Pearson, P.A., Comstock, T.L., Ip, M. et al. Fluocinolone acetonide intravitreal implant for diabetic macular edema: a 3- year multicenter, randomized controlled clinical trial. Ophthalmology 2011, 118(8): 1580-7.
27. Campochiaro, P.A., Brown, D.M., Pearson, A. et al. Sustained delivery fluocinolone acetonide vitreous inserts provide benefit for at least 3 years in patients with diabetic macular edema. Ophthalmology 2012, 119(10): 2125-32.
28. Haller, J.A., Kuppermann, B.D., Blumenkranz, M.S., Williams, G.A., Weinberg, D.V., Chou, C., Whitcup, S.M. Randomized controlled trial of an intravitreous dexamethasone drug delivery system in patients with diabetic macular edema. Arch Ophthalmol 2010, 128(3): 289-96.
29. Mitchell, P., Bandello, F., Schmidt-Erfurth, U. et al. The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology 2011, 118(4): 615-25.
30. Diabetic Retinopathy Clinical Research, N., Elman, M.J., Aiello, L.P. et al. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 2010, 117(6): 1064-77.e35.
31. Elman, M.J., Bressler, N.M., Qin, H. et al. Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 2011, 118(4): 609-14.
32. Comyn, O., Lightman, S.L., Hykin, P.G. Corticosteroid intravitreal implants vs. ranibizumab for the treatment of vitreoretinal disease. Curr Opin Ophthalmol 2013, 24(3): 248-54.
33. Maca, S.M., Abela-Formanek, C., Kiss, C.G., Sacu, S.G., Benesch, T., Barisani-Asenbauer, T. Intravitreal triamcin - olone for persistent cystoid macular oedema in eyes with quiescentuveitis. Clin Experiment Ophthalmol 2009, 37(4):389-96.
34. Sallam, A., Taylor, S.R., Habot-Wilner, Z., Elgohary, M., Do,H.H., McCluskey, P., Lightman, S. Repeat intravitreal triamcinolone acetonide injections in uveitic macular oedema. Acta Ophthalmol 2012, 90(4): e323-5.
35. Tuncer, S., Yilmaz, S., Urgancioglu, M., Tugal-Tutkun, I. Results of intravitreal triamcinolone acetonide (IVTA) injection for the treatment of panuveitis attacks in patients with Behcet disease. J Ocul Pharmacol Ther 2007, 23(4): 395 401. (Pubitemid 350195065)
36. Multicenter Uveitis Steroid Treatment Trial Research Group,Kempen, J.H., Altaweel, M.M. et al. Randomized comparison of systemic anti-inflammatory therapy versus fluocinolone acetonide implant for intermediate, posterior, and panuveitis: the multicenter uveitis steroid treatment trial. Ophthalmology 2011, 118(10): 1916-26.
37. Lowder, C., Belfort, R., Jr., Lightman, S. et al.Dexamethasone intravitreal implant for noninfectious intermediate or posterior uveitis. Arch Ophthalmol 2011, 129(5):545-53.
38. Taylor, S.R., Tomkins-Netzer, O., Joshi, L., Morarji, J.,McLoone, E., Lightman, S. Dexamethasone implant in pediatric uveitis. Ophthalmology 2012, 119(11): 2412.e2.
39. Hazirolan, D., Pleyer, U. Think global-act local: intravitreal drug delivery systems in chronic noninfectious uveitis. Ophthalmic Res 2013, 49(2): 59-65.
40. Gharbiya, M., Cruciani, F., Cuozzo, G., Parisi, F., Russo, P.Abdolrahimzadeh, S. Macular thickness changes evaluated with spectral domain optical coherence tomography after uncomplicated phacoemulsification. Eye 2013, 27(5): 605-11.
41. Benitah, N.R., Arroyo, J.G. Pseudophakic cystoid macular edema. Int Ophthalmol Clin 2010, 50(1): 139-53.
42. Henderson, B.A., Kim, J.Y., Ament, C.S., Ferrufino-Ponce,Z.K., Grabowska, A., Cremers, S.L. Clinical pseudophakic cystoid macular edema; risk factors for development and duration after treatment. J Cataract Refract Surg 2007, 33(9): 1550-8. (Pubitemid 47304389)
43. Lobo, A.M., Sobrin, L., Papaliodis, G.N. Drug delivery optionsfor the treatment of ocular inflammation. Semin Ophthalmol 2010, 25(5-6): 283-8.
44. Ghasemi Falavarjani, K., Parvaresh, M.M., Modarres, M.,Hashemi, M., Samiy, N. Intravitreal bevacizumab for pseudophakic cystoid macular edema; a systematic review. J Ophthalmic Vis Res 2012, 7(3): 235-9.
45. Kuppermann, B.D., Blumenkranz, M.S., Haller, J.A. et al. Randomized controlled study of an intravitreous dexamethasone drug delivery system in patients with persistent macular edema. Arch Ophthalmol 2007, 125(3): 309-17. (Pubitemid 46425557)
46. Kiddee, W., Trope, G.E., Sheng, L. et al. Intraocular pressure monitoring post intravitreal steroids: a systematic review. Surv Ophthalmol 2013, 58(4): 291-310.
47. Goldstein, D.A., Godfrey, D.G., Hall, A. et al. Intraocular pressure in patients with uveitis treated with fluocinolone acetonide implants. Arch Ophthalmol 2007, 125(11): 1478-85. (Pubitemid 350106679)
48. Bollinger, K., Kim, J., Lowder, C.Y., Kaiser, P.K., Smith, S.D. Intraocular pressure outcome of patients with fluocinolone acetonide intravitreal implant for noninfectious uveitis. Ophthalmology 2011, 118(10): 1927-31.
49. Pearson, P.A., Comstock, T.L., Ip, M. et al. Fluocinolone acetonide intravitreal implant for diabetic macular edema: a 3-year multicenter, randomized, controlled clinical trial.Ophthalmology 2011, 118(8): 1580-7.
50. Boyer, D.S., Faber, D., Gupta, S. et al. Dexamethasoneintravitreal implant for treatment of diabetic macular edema in vitrectomized patients. Retina 2011, 31(5): 915-23.
51. Haller, J.A., Dugel, P., Weinberg, D.V., Chou, C., Whitcup,S.M. Evaluation of the safety and performance of an applicator for a novel intravitreal dexamethasone drug delivery systemfor the treatment of macular edema. Retina 2009, 29(1):46-51.
52. Williams, G.A., Haller, J.A., Kuppermann, B.D. et al. Dexamethasone posterior-segment drug delivery system in the treatment of macular edema resulting from uveitis or Irvine-Gass syndrome. Am J Ophthalmol 2009, 147(6): 1048-54.e2.
53. Taban, M., Lowder, C.Y., Kaiser, P.K. Outcome of fluocinoloneacetonide implant (Retisert) reimplantation for chronic noninfectiousposterior uveitis. Retina 2008, 28(9): 1280-8.
54. Khurana, R.N., Appa, S.N., McCannel, C.A. et al.Dexamethasone implant anterior chamber migration: risk factors, complications, and management strategies. Ophthalmology 2014, 121(1): 67-71.
55. Parodi, M.B., Iacono, P., De Benedetto, U., Cascavilla, M.,Bandello, F. Rebound effect after intravitreal dexamethasone implant for the treatment of macular edema secondary to central retinal vein occlusion. J Ocul Pharmacol Ther 2012,28(6): 566-8.
56. Bakri, S.J., Omar, A.F. Evolution of vitreomacular traction followingthe use of the dexamethasone intravitreal implant (Ozurdex) in the treatment of macular edema secondary to central retinal vein occlusion. J Ocul Pharmacol Ther 2012, 28(5): 547-9.
57. ECT Platform. Neurotech. http://www.neurotechusa.com/ ect-platform.html. Accessed March 3, 2014.
58. Verisome- Technology Overview. Icon Bioscience, Inc. www.iconbioscience. com/Technology-Overview.html. Accessed March 3, 2014.
59. Kuppermann, B.D. Implant delivery of corticosteroids and other pharmacologic agents. Retina 2006 (November 10-11, Las Vegas) 2006.
60. Barnett, P.J. Mathematical modeling of triamcinolone acetonide drug release from the I-Vation intravitreal implant (a controlled release platform). Conf Proc IEEE Eng Med Biol Soc (September 3-6, Minneapolis) 2009, 13: 3087-90.
61. Choonara, Y.E., Pillay, V., Carmichael, T., Danckwerts, M.P. Studies on a novel doughnut-shaped minitablet for intraocular drug delivery. AAPS Pharm Sci Tech 2007, 8(4): 1-7 E118.
62. Palakurthi, N.K., Correa, Z.M., Augsburger, J.J., Banerjee, R.K. Toxicity of a biodegradable microneedle implant loaded with methotrexate as a sustained release device in normal rabbit eye: a pilot study. J Ocul Pharmacol Ther 2011, 27(2):151-6.
63. He, Y., Liu, Y., Liu, Y. et al. Cyclosporine-loaded microspheres for treatment of uveitis: in vitro characterization and in vivo pharmacokinetic study. Invest Ophthalmol Vis Sci 2006, 47(9): 3983-8. (Pubitemid 46044315)
64. Kompella, U.B., Kadam, R.S., Lee, V.H. Recent advances in ophthalmic drug delivery. Ther Deliv 2010, 1(3): 435-56.
65. Kadam, R.S., Tyagi, P., Edelhauser, H.F., Kompella, U.B. Influence of choroidal neovascularization and biodegradable polymeric particle size on transscleral sustained delivery of triamcinolone acetonide. Int J Pharm 2012, 434(1-2): 140-7.
66. Giannaccini, M., Giannini, M., Calatayud, M.P., Goya, G.F., Cuschieri, A., Dente, L., Raffa, V. Magnetic nanoparticles as intraocular drug delivery system to target retinal pigmented epithelium (RPE). Int J Mol Sci 2013, 15(1): 1590-605.